Alyeska Investment Group
BPMC

Alyeska Investment Group’s Blueprint Medicines BPMC Stock Holding History

Alyeska Investment Group’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-50,000
Closed -$4.43M – 572
2025
Q1 		$4.43M Buy
+50,000
New +$4.88M 0.02% 370
2020
Q3 		– Sell
-296,858
Closed -$23.2M – 473
2020
Q2 		$23.2M Buy
296,858
+95,124
+47% +$6.43M 0.35% 101
2020
Q1 		$11.8M Buy
201,734
+161,482
+401% +$10.4M 0.23% 116
2019
Q4 		$3.23M Buy
+40,252
New +$3.01M 0.04% 253
2019
Q2 		– Sell
-169,505
Closed -$13.6M – 446
2019
Q1 		$13.6M Buy
+169,505
New +$12.5M 0.18% 149
2018
Q3 		– Sell
-119,758
Closed -$7.6M – 416
2018
Q2 		$7.6M Buy
119,758
+45,602
+61% +$3.63M 0.07% 240
2018
Q1 		$6.8M Buy
74,156
+3,665
+5% +$316K 0.06% 264
2017
Q4 		$5.32M Sell
70,491
-29,509
-30% -$2.08M 0.04% 259
2017
Q3 		$6.97M Buy
+100,000
New +$5.34M 0.05% 269
2017
Q2 		– Sell
-59,746
Closed -$2.39M – 458
2017
Q1 		$2.39M Sell
59,746
-40,254
-40% -$1.44M 0.02% 384
2016
Q4 		$2.81M Buy
+100,000
New +$3.01M 0.02% 371
2016
Q3 		– Sell
-183,740
Closed -$3.72M – 461
2016
Q2 		$3.72M Buy
183,740
+91,903
+100% +$1.67M 0.04% 325
2016
Q1 		$1.66M Buy
91,837
+17,556
+24% +$305K 0.02% 341
2015
Q4 		$1.96M Sell
74,281
-9,633
-11% -$217K 0.02% 309
2015
Q3 		$1.79M Buy
83,914
+7,679
+10% +$212K 0.02% 339
2015
Q2 		$2.02M Buy
+76,235
New +$2.18M 0.02% 350

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Alyeska Investment Group's BPMC Position: Q2 2025 in Review

Alyeska Investment Group sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 50,000 shares — an estimated $4.43M sold.

Alyeska Investment Group first reported a position in BPMC in Q2 2015 and held it in 16 quarters. The position peaked at $23.2M in Q2 2020. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • Alyeska Investment Group reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • Alyeska Investment Group sold 50,000 Blueprint Medicines shares in Q2 2025, an estimated $4.43M.
  • Alyeska Investment Group first reported a position in Blueprint Medicines in Q2 2015 and held it in 16 quarters.
  • Alyeska Investment Group's Blueprint Medicines position peaked at $23.2M in Q2 2020.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Alyeska Investment Group's 13F filing for Q2 2025, filed 14 Aug 2025.